Compare ABUS & NAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | NAT |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | Bermuda |
| Employees | 19 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.8M | 914.8M |
| IPO Year | 2008 | 1997 |
| Metric | ABUS | NAT |
|---|---|---|
| Price | $4.25 | $5.48 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 2 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | 1.6M | ★ 3.7M |
| Earning Date | 05-14-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 8.50% |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $14,083,000.00 | N/A |
| Revenue This Year | N/A | $77.72 |
| Revenue Next Year | $239.71 | N/A |
| P/E Ratio | ★ $4.95 | $525.49 |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.04 | $2.55 |
| 52 Week High | $5.10 | $6.34 |
| Indicator | ABUS | NAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.31 | 42.56 |
| Support Level | $4.17 | $5.39 |
| Resistance Level | $4.62 | $6.30 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 46.23 | 12.70 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.